Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Type 1 Diabetes Mellitus: early-phase trial registry
25 of 113 indexed Type 1 Diabetes Mellitus trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #113 of 28,707 conditions by registered trial count.
113 US clinical trials · 25 currently recruiting · #113 of 28,707 conditions by registered trial count
Type 1 Diabetes Mellitus: 113 US clinical trials tracked, 25 recruiting.
Type 1 Diabetes Mellitus is the subject of 113 registered US clinical trials on ClinicalTrials.gov, 25 of them currently open to new participants. 19 are in Phase 3-4 (later-stage) and 38 in Phase 1-2 (earlier-stage). The most active sponsor is University of Virginia, running 9 of these trials.
Enrollment posture brief
Registry condition type-1-diabetes-mellitus
OPEN 25 | RECR 22% | LATE 19 | EARLY 38 | RANK #113 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Acne (22% recruiting · 27 trials)
Type 1 Diabetes Mellitus lists 25 open slots (22% of 113 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Type 1 Diabetes Mellitus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Type 1 Diabetes Mellitus is recruiting below its size-band peers.
25 of 113 indexed trials (22.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Type 1 Diabetes Mellitus trials is spread across many organizations.
University of Virginia accounts for 9 of 113 trials (8%). 67 distinct sponsors appear on at least one study for this condition label.
-
Most Type 1 Diabetes Mellitus trials plan to enrol fewer than 100 people.
Median target enrolment is 48 among the 113 trials that report a genuine target (sentinel values excluded). 80 of those (70.8%) plan for fewer than 100 participants.
-
Type 1 Diabetes Mellitus research is mostly interventional.
95 interventional and 18 observational studies make up this index (84.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
113 total, page 1 of 3
Genetics Of Autoimmunity In Type I Diabetes
Medical College of Wisconsin
NCT03648918
Twiist Postmarket Surveillance Study for Type 1 Diabetes
Deka Research and Development
NCT07356089
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Sanofi
NCT07088068
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
Medtronic Diabetes
NCT07228117
A Hybrid Effectiveness-implementation Trial to Reduce Diabetes Distress in Teenagers
Ann & Robert H Lurie Children's Hospital of Chicago
NCT06709755
EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)
University of Exeter
NCT03369821
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
Sanofi
NCT06111586
Dapagliflozin Plus Pioglitazone in T1DM
The University of Texas Health Science Center at San Antonio
NCT03878459
Type 1 Diabetes Extension Study
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02734277
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
Mannkind Corporation
NCT07224321
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
COUR Pharmaceutical Development Company
NCT06783309
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
University of Chicago
NCT06305286
The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System
Joslin Diabetes Center
NCT05754281
The Effects of Fluoxetine and/or DHEA
University of Maryland, Baltimore
NCT03228732
Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)
Children's Mercy Hospital Kansas City
NCT06390371
Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss
Rodolfo Alejandro
NCT02000687
Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM
i-SENS
NCT07296276
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
Estar Medical dba Medical Technologies
NCT06810726
Long Term Follow up of Recipients of Functional Islet Allografts
Rodolfo Alejandro
NCT01999374
Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes
Vanderbilt University Medical Center
NCT06609356
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
Stanford University
NCT07090824
PACTAID App in Adults With Type 1 Diabetes to Help Manage Exercise
Mayo Clinic
NCT06730906
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
Rodolfo Alejandro
NCT01999361
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
GentiBio
NCT06919354
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
Otsuka Pharmaceutical Factory
NCT06575426
Home Video-based Telemedicine to Reduce Hypoglycemia Fear in Parents of Young Children
Nemours Children's Clinic
NCT03914547
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
Diamyd Medical AB
NCT05018585
Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus
Luna Diabetes
NCT06627517
Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule
Sanofi
NCT06812988
Triple Therapy in T1DM
State University of New York at Buffalo
NCT03899402
Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT03929601
Reducing Innate Inflammation in New Onset Type 1 Diabetes
Medical College of Wisconsin
NCT04335656
MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus
University of Colorado, Denver
NCT03945747
Probiotics in Newly Diagnosed T1D
Medical College of Wisconsin
NCT04141761
Impact of Metabolic Health on Sperm Epigenetic Marks in Humans
Joslin Diabetes Center
NCT03860558
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
CellTrans
NCT00679042
A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation
Sernova Biotherapeutics
NCT03513939
Islet Cell Transplant for Type 1 Diabetes
City of Hope Medical Center
NCT01909245
An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes
City of Hope Medical Center
NCT04590872
A Study of LY900014 in Participants With Type 1 Diabetes
Eli Lilly and Company
NCT03214367
An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
AstraZeneca
NCT00229658
The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
MacroGenics
NCT00385697
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus
Sanofi
NCT01683266
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
Mannkind Corporation
NCT01445951
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
Halozyme Therapeutics
NCT01848990
Positive Psychology Intervention to Treat Diabetes Distress in Teens With Type 1 Diabetes
Vanderbilt University Medical Center
NCT03845465
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
Provention Bio
NCT03875729
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
Medtronic Diabetes
NCT04436822
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
Bayer
NCT05901831
Technological Advances in Glucose Management in Older Adults
Joslin Diabetes Center
NCT03078491
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 20 |
| Phase 2 | 18 |
| Phase 3 | 14 |
| Phase 4 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Type 1 Diabetes Mellitus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Type 1 Diabetes Mellitus trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Type 1 Diabetes Mellitus page
113 registered trials, 25 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 25 Type 1 Diabetes Mellitus trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Virginia sponsors the most Type 1 Diabetes Mellitus trials on record, review their full trial history before evaluating a specific study. See University of Virginia's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Type 1 Diabetes Mellitus condition card totals 113 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.